FY2024 Earnings Forecast for Sanofi Issued By Zacks Research

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Sanofi in a research note issued to investors on Wednesday, November 13th. Zacks Research analyst K. Shah now expects that the company will earn $4.31 per share for the year, up from their previous estimate of $4.12. The consensus estimate for Sanofi's current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Sanofi's Q4 2024 earnings at $0.84 EPS, Q1 2026 earnings at $1.17 EPS and Q2 2026 earnings at $1.16 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi's quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $2.55 EPS.

A number of other brokerages also recently issued reports on SNY. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a report on Friday, July 26th. StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 7th. Finally, Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Stock Up 1.1 %

Shares of SNY traded up $0.54 during mid-day trading on Monday, hitting $48.51. 2,613,919 shares of the company traded hands, compared to its average volume of 2,040,932. The business has a 50 day moving average of $54.45 and a 200 day moving average of $52.22. The company has a market capitalization of $123.11 billion, a PE ratio of 24.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently bought and sold shares of the company. Manning & Napier Advisors LLC purchased a new position in shares of Sanofi in the 2nd quarter valued at about $13,725,000. Mount Yale Investment Advisors LLC raised its holdings in Sanofi by 44.3% during the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company's stock worth $2,027,000 after purchasing an additional 12,806 shares during the last quarter. GFS Advisors LLC boosted its position in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after purchasing an additional 11,655 shares in the last quarter. Atria Investments Inc grew its holdings in Sanofi by 31.1% in the first quarter. Atria Investments Inc now owns 98,878 shares of the company's stock valued at $4,805,000 after purchasing an additional 23,463 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its position in shares of Sanofi by 15.2% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company's stock valued at $5,673,000 after buying an additional 15,439 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.